Overexpression of low-molecular-weight caldesmon is associated with aggressive phenotypes and epithelial-mesenchymal transition in breast cancer cells

Table 1 Breast cancer cell lines used in this study and their tumor origin[32,45]

Cell line	Tumor source	Breast cancer subtypes
MCF7	Adenocarcinoma of the mammary gland; cells were obtained from a metastatic site (pleural effusion)	Luminal A (ER+ and/or PR+ HER2-)
MDA-MB-361	Adenocarcinoma of the mammary gland; cells were obtained from a metastatic site (brain)	Luminal (ER+, PR-, and HER2+ amplified)
ZR-75-1	Ductal carcinoma of the mammary gland; cells were obtained from a metastatic site (ascites)	Luminal A (ER+ and/or PR+ HER2-)
CAL-51	Adenocarcinoma isolated from malignant pleural effusion of metastatic breast cancer, normal karyotype with genetic stability	Triple-negative (ER-, PR-, HER2-)
1001	Derived from parental MCF7 (MCF7/R-A1), which are cells exposed to increasing doses of recombinant TNF, transfected with p55 TNF receptor cDNA, mutation in R280K	Luminal A (ER+ and/or PR+ HER2-)
MDA-MB-231	Adenocarcinoma of the mammary gland, cells were obtained from the metastatic site; pleural effusion	Basal subtype receptor status: Triple-negative (ER-, PR- HER2-)
T47D	Ductal carcinoma of the mammary gland, cells were obtained from the metastatic site; pleural effusion	Luminal B (ER+ and/or PR+ HER2+/-)
BT-549	Ductal carcinoma of the mammary gland, cells were obtained from the mammary gland	Basal B subtype receptor status: Triple-negative (ER-, PR-, HER2-)

BC: Breast cancer; ER: Estrogen receptor; PR: Progesterone receptor; TNF: Tumor necrosis factor.